Related Experiment Videos
p16 overexpression: a potential early indicator of transformation in ovarian carcinoma
1Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, USA.
Objective:
The recently cloned gene p16 (MST1) has been identified as a putative tumor suppressor gene that binds to CDK4 and CDK6 (cyclin-dependent kinases), preventing their interaction with cyclin D1 and thereby preventing cell cycle progression at the G1 stage. In addition, the p16 gene has been shown to have a high frequency of mutation in some tumor cell lines; however, it has also been shown that a much lower frequency of mutation occurs in primary tumors. This study investigated the mRNA expression level and mutation status of the p16 gene in ovarian tumors.
Methods:
We performed quantitative polymerase chain reaction and direct cDNA sequencing analysis. To confirm the p16 protein level in ovarian tumors, Western blotting and immunohistochemical staining were performed. Expression levels of mRNA for the p16 gene relative to the beta-tubulin gene were examined in 32 ovarian tumors (24 carcinomas, six low malignant potential tumors, and two benign tumors) and six normal ovaries.
Results:
The mRNA expression level of p16 was significantly elevated in 28 ovarian tumors (22 carcinomas, five low malignant potential tumors, and one benign tumor) compared with that of normal ovaries. Western blotting analysis and immunohistochemical staining confirmed elevated p16 protein levels in ovarian tumor samples. Among 32 ovarian tumors, cDNA sequencing of the p16 gene showed no p16 mutation resulting in a coding error, although one silent mutation and three polymorphisms were found.
Conclusions:
Although p16 is seldom mutated in ovarian tumors, the overexpression of p16 in most ovarian tumor cases indicates a dysfunction in the regulatory complex for G1 arrest. Therefore, overexpression of p16 may be an important early event in the neoplastic transformation of the ovarian epithelium.
Insights
Ovarian tumors frequently overexpress the p16 gene, a cell cycle regulator. Despite rare mutations, this overexpression suggests a role in ovarian cancer development, potentially an early event in neoplastic transformation.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The p16 gene acts as a tumor suppressor by inhibiting cell cycle progression at G1.
- While p16 mutations are noted in cell lines, their frequency in primary tumors is lower.
- Investigating p16 in ovarian tumors is crucial for understanding its role in tumorigenesis.
Purpose of the Study:
- To analyze the mRNA expression and mutation status of the p16 gene in ovarian tumors.
- To correlate p16 expression and mutation with ovarian tumor characteristics.
Main Methods:
- Quantitative polymerase chain reaction (qPCR) for mRNA expression analysis.
- Direct cDNA sequencing for mutation detection.
- Western blotting and immunohistochemistry for protein level confirmation.
Main Results:
- Significantly elevated p16 mRNA and protein levels were observed in most ovarian tumors compared to normal ovaries.
- No coding mutations were detected in the p16 gene across 32 ovarian tumors.
- One silent mutation and three polymorphisms were identified, but no functional mutations.
Conclusions:
- p16 gene mutations are infrequent in ovarian tumors.
- Overexpression of p16 in ovarian tumors suggests a regulatory defect in the G1 cell cycle arrest pathway.
- p16 overexpression may represent an early event in ovarian epithelial neoplastic transformation.